Curis Inc. Announces New Clinical Study of Emavusertib in Combination with BTK Inhibitor for Chronic Lymphocytic Leukemia

Reuters

08/05

Curis Inc. Announces New Clinical Study of Emavusertib in Combination with BTK Inhibitor for Chronic Lymphocytic Leukemia

Curis Inc., a biotechnology company specializing in the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, has announced upcoming milestones in its clinical research. The company is set to present additional data from the TakeAim Lymphoma study, specifically concerning R/R PCNSL patients, later this year. Furthermore, Curis is conducting an ongoing triplet study that evaluates different dosing regimens of emavusertib, venetoclax, and azacitidine in frontline acute myeloid leukemia $(AML.AU)$ patients. Data from this study is anticipated to be shared at the 67th American Society of Hematology $(ASH)$ Annual Meeting in December.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001108205-25-000079), on August 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557999113"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557999113\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557999113?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557999113","market":"nz","top_or_hot":-1,"title":"Curis Inc. Announces New Clinical Study of Emavusertib in Combination with BTK Inhibitor for Chronic Lymphocytic Leukemia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Curis Inc. Announces New Clinical Study of Emavusertib in Combination with BTK Inhibitor for Chronic Lymphocytic Leukemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Curis Inc., a biotechnology company specializing in the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, has announced upcoming milestones in its clinical research. The company is set to present additional data from the TakeAim Lymphoma study, specifically concerning R/R PCNSL patients, later this year. Furthermore, Curis is conducting an ongoing triplet study that evaluates different dosing regimens of emavusertib, venetoclax, and azacitidine in frontline acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> patients. Data from this study is anticipated to be shared at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting in December.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001108205-25-000079), on August 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Curis Inc. Announces New Clinical Study of Emavusertib in Combination with BTK Inhibitor for Chronic Lymphocytic Leukemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCuris Inc. Announces New Clinical Study of Emavusertib in Combination with BTK Inhibitor for Chronic Lymphocytic Leukemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-05 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Curis Inc. Announces New Clinical Study of Emavusertib in Combination with BTK Inhibitor for Chronic Lymphocytic Leukemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Curis Inc., a biotechnology company specializing in the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, has announced upcoming milestones in its clinical research. The company is set to present additional data from the TakeAim Lymphoma study, specifically concerning R/R PCNSL patients, later this year. Furthermore, Curis is conducting an ongoing triplet study that evaluates different dosing regimens of emavusertib, venetoclax, and azacitidine in frontline acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> patients. Data from this study is anticipated to be shared at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting in December.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001108205-25-000079), on August 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRIS","symbol_name":"居里","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL2yhF1T:1","article_id":"2557999113","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557999113","pubTimestamp":1754395674,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Curis Inc., a biotechnology company specializing in the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, has announced upcoming milestones in its clinical research. The company is set to present additional data from the TakeAim Lymphoma study, specifically concerning R/R PCNSL patients, later this year. Furthermore, Curis is conducting an ongoing triplet study that evaluates different dosing regimens of emavusertib, venetoclax, and azacitidine in frontline acute myeloid leukemia  patients. Data from this study is anticipated to be shared at the 67th American Society of Hematology  Annual Meeting in December.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRIS":"居里","BK4139":"生物科技"},"translate_title":"Curis Inc.宣布Emavusertib联合BTK抑制剂治疗慢性淋巴细胞白血病的新临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRIS":0.9},"content_text":"Curis Inc. Announces New Clinical Study of Emavusertib in Combination with BTK Inhibitor for Chronic Lymphocytic Leukemia\n    \n\n        Curis Inc., a biotechnology company specializing in the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, has announced upcoming milestones in its clinical research. The company is set to present additional data from the TakeAim Lymphoma study, specifically concerning R/R PCNSL patients, later this year. Furthermore, Curis is conducting an ongoing triplet study that evaluates different dosing regimens of emavusertib, venetoclax, and azacitidine in frontline acute myeloid leukemia $(AML.AU)$ patients. Data from this study is anticipated to be shared at the 67th American Society of Hematology $(ASH)$ Annual Meeting in December.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001108205-25-000079), on August 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}